Thereby, VEGF in patient plasma and serum has been under investigation as a potential biomarker for HNSCC [15,32,33,42,43], but decision making regarding sampling plasma or serum for VEGF measurements, with the achievement of biomarker identification, has not been standardized [24] and is inconsistently used, as seen in several studies [15,32]. The gene discussed is VEGFA; the disease is head and neck squamous cell carcinoma.